The new temperature-sensitive mutation PA-F35S for developing recombinant avian live attenuated H5N1 influenza vaccine

Wenting Zhang, Jiagang Tu, Zongzheng Zhao, Huanchun Chen and Meilin Jin*

Abstract

Background: H5N1 highly pathogenic avian influenza virus (HPAIV) is continuously circulating in many Asian countries and threatening poultry industry and human population. Vaccination is the best strategy to control H5N1 HPAIV infection in poultry and transmission to human population. The aim of this study is to identify new temperature-sensitive (ts) mutations for developing recombinant avian live attenuated H5N1 influenza vaccine.

Findings: A "6+2" recombinant virus C4/W1 that contained NA gene and modified HA gene from virus A/chicken/Hubei/327/2004 (H5N1) (C4), and six internal genes from virus A/duck/Hubei/W1/2004 (H9N2) (W1) was generated using reverse genetics and subsequently passaged in chicken eggs at progressively lower temperatures (32°C, 28°C and 25°C). The resulting virus acquired ts phenotype and one of its amino acid mutations, PA (F35S), was identified as ts mutation. Furthermore, when used as live attenuated vaccine, the recombinant virus with this ts mutation PA (F35S) provided efficient protection for chickens against H5N1 HPAIV infection.

Conclusions: These findings highlight the potential of the new ts mutation PA (F35S) in developing recombinant avian live attenuated H5N1 influenza vaccine.

Keywords: Influenza, H5N1, Vaccine, Live attenuated

Findings

H5N1 HPAIV is continuously circulating in many Asian countries and threatening poultry industry and human population. An effective vaccine to protect poultry from infections of H5N1 HPAIV is needed not only to reduce economic losses in the poultry industry, but also to minimize virus transmission from infected poultry to humans [1].

Live attenuated influenza vaccine (LAIV) with needle-free intranasal administration and cross-protection is attractive in controlling pandemic influenza. Recombinant influenza virus with C-terminal truncated NS1, deficient NA, cleavage-site modified HA or cytoplasmatic-tail deleted M2 has been reported as LAIV [2-5]. Besides these, low-temperature passage has been commonly used to acquire LAIV with ts phenotype [6-8]. The ts mutations were identified in internal genes of the LAIVs [9], and some LAIVs were subsequently used as master donor virus (MDV) to generate new LAIVs by reassortment with two surface glycoprotein genes from currently epidemic strains [10-13].

LAIV has been widely used in humans, while rare LAIV was reported to be used for poultry. Lee et al. developed an avian H9N2 LAIV by successively passaged a wild-type H9N2 influenza virus A/Chicken/Korea/S1/03 in embryonated chicken eggs at progressively lower temperatures [7]. Although the ts mutations of the avian H9N2 LAIV were not identified, some of the amino acid mutations (PB2N265S, PB1K391E/E581G/A661T and NP0D34G) were similar to the ts mutations of the MDV A/Ann Arbor/6/60 (H2N2). However, transferring these ts mutations (PB2N265S, PB1K391E/E581G/A661T and NP0D34G) into the corresponding internal genes of an avian H9N2 influenza virus A/Guinea Fowl/Hong Kong/WF10/99 could not sufficiently result in an avian live attenuated H9N2 influenza backbone, further introduction of a HA tag into PB1 gene was needed [14]. This strategy of generating avian live attenuated H9N2 influenza backbone

* Correspondence: jinmeilin@mail.hzau.edu.cn
Unit of Animal Infectious Diseases, National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, P. R. China

© 2012 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
seemed inconvenient, more simple ts mutations needed to be identified.

Therefore, the aim of this study was to acquire new and simple ts mutations within an avian H9N2 influenza backbone for developing recombinant avian live attenuated H5N1 influenza vaccine. All experiments with H5N1 HPAIV were performed in ABSL-3 containment facility. We initially generated a “6 + 2” recombinant virus C4/W1 that contained NA gene and modified HA gene (cleavage site was changed from PQRERRKKG to low pathogenic characteristic PQETR [G] [15] from H5N1 influenza virus A/Chicken/Hubei/327/2004 (C4) [16], and six internal genes from H9N2 influenza virus A/Duck/Hubei/ W1/2004 (W1) [17]. Recombinant virus C4/W1 was then serially passaged in chicken eggs for 10 times at 32°C and 28°C respectively and 15 times at 25°C [7,8].

The ts phenotype of this low-temperature passaged virus was evaluated. Six 10-day-old specific-pathogen-free (SPF) chicken eggs were inoculated with 10³ EID₅₀ of the low-temperature passaged virus (0.2 ml/egg) and incubated at 37°C or 41°C for 48 hours, the parent virus C4/W1 was used as comparison. Allantoic fluids were collected and viral titers were determined by 50% egg infectious dose (EID₅₀) at 37°C. Virus could be considered ts if it displayed 100-fold or greater reduction in viral titers at 41°C compared with that observed at 37°C. As shown in Figure 1, virus C4/W1 and the low-temperature passaged virus grew efficiently at 37°C (9.3 or 9.1 log₁₀ EID₅₀/ml, respectively). Nevertheless, at 41°C, the virus C4/W1 still grew up to high viral titers (9.0 log₁₀ EID₅₀/ml), while the low-temperature passaged virus was highly impaired in growth (under limited detection). These results indicated that the low-temperature passaged virus acquired ts phenotype and was named ts-C4/W1.

Subsequently, eight gene segments of the virus ts-C4/W1 were sequenced and compared with that of virus C4/W1.

To determine whether recombinant virus with the ts mutation PA (F35S) was attenuated in chickens, pathogenicity and growth property of the single-mutation recombinant virus C4/W1-PA (F35S) was assessed, viruses ts-C4/W1 and C4/W1 were used as comparison. Animal studies were performed according to protocols approved by the Hubei Provincial Animal Care and Use Committee. The intravenous pathogenicity index (IVPI) was performed [15] and indicated that virus C4/W1-PA (F35S) (IVPI = 0) as well as virus ts-C4/W1 (IVPI = 0) was more attenuated than virus C4/W1 (IVPI = 0.8). To assess growth property, groups of 3-week-old White Leghorn chickens were inoculated intranasally (i.n.) with 0.2 ml 10⁶ EID₅₀ of the single-mutation recombinant virus C4/W1-PA (F35S), ts-C4/W1 or C4/W1. At 3 and 5 days post-inoculation (p.i.), four chickens in each group were sacrificed, tracheal swabs, cloacal swabs and lungs were collected in 1 ml phosphate buffered saline (PBS) containing penicillin and streptomycin, lungs were homogenized. Viral titers were determined by EID₅₀ at 37°C. Virus C4/W1 grew efficiently in chickens and could be detected in tracheal swabs, cloacal swabs and lungs of inoculated chickens with high viral titers at 3 and 5 days p.i.; virus ts-C4/W1 couldn’t be detected in any swabs or lungs of the inoculated chickens; while virus C4/W1-PA (F35S) could only be detected in the tracheal swabs of inoculated chickens at 3 days p.i. with much less viral titers (1.8 log₁₀ EID₅₀/ml) (Table 1). All these data showed that the single-mutation recombinant virus C4/W1-PA (F35S) as well as virus ts-C4/W1 was non-pathogenic to chickens and highly impaired in growth in chickens, which was critically important as LAIV.

In addition, live attenuated vaccine must be non-pathogenic to vaccine operators before used in poultry. Here, mice were used to assess the virulence of virus C4/W1-PA (F35S). The fifty percent mouse lethal dose (MLD₅₀) was determined as described previously [15]. As shown in Table 1, virus C4/W1-PA (F35S) and virus ts-C4/W1 were more attenuated (MLD₅₀ > 8.0 log₁₀ EID₅₀/50 μl) in mice than virus C4/W1 (MLD₅₀ = 6.5 log₁₀ EID₅₀/50 μl). This phenotype of attenuation could also be observed from body weight loss of mice infected i.n. with 50 μl 10⁶ EID₅₀ of virus C4/W1-PA (F35S), ts-C4/W1 or C4/W1. Virus C4/W1 caused maximum 20% of initial body weight loss, while no apparent body weight loss was observed when mice infected with virus C4/W1-PA (F35S) or ts-C4/W1 (Data not shown). Their growth ability in mice was also determined. Groups of 6-week-old female BALB/c mice were inoculated i.n. with 50 μl 10⁶ EID₅₀ of virus C4/W1-PA (F35S), ts-C4/W1 or C4/W1. At
Table 1 Pathogenicity and growth property of recombinant viruses in chickens and mice

| Viruses       | IVPI | Virus replication in chickens* (log_{10}EID50/ml ± SE) | MLD_{50} (log_{10}EID50/50 μl) | Virus replication in mice* (log_{10}EID50/ml ± SE) |
|---------------|------|-------------------------------------------------------|-------------------------------|-----------------------------------------------|
|               |      | Day 3 Trachea | Cloacal | Lungs | Day 5 Trachea | Cloacal | Lungs | Day 3 | Day 6 |
| C4/W1         | 0.8  | 4/4 (3.9 ± 0.4) | 4/4 (2.4 ± 0.5) | 4/4 (3.5 ± 0.2) | 4/4 (5.4 ± 0.2) | 3/4 (3.3 ± 0.3) | 4/4 (4.7 ± 0.6) | 6.5  | 3/3* (4.6 ± 0.2) | 3/3 (3.3 ± 0.3) |
| ts-C4/W1      | 0    | 0/4          | 0/4     | 0/4   | 0/4          | 0/4     | 0/4   | >8.0  | 2/3 (1.6 ± 0.1) | 0/3 |
| C4/W1-PA(F35S)| 0    | 4/4 (1.8 ± 0.3) | 0/4     | 0/4   | 0/4          | 0/4     | 0/4   | >8.0  | 3/3 (3.4 ± 0.3) | 2/3 (2.5 ± 0.1) |

Note: IVPI, intravenous pathogenicity index; MLD_{50}, 50% mouse lethal dose; EID_{50}, 50% egg infectious dose; SE, standard errors.

* Groups of chickens were inoculated intranasally with 0.2 ml 10^6 EID_{50} of the indicated viruses. At 3 and 5 days post-inoculation, viral titers in tracheal swabs, cloacal swabs and lungs were determined by testing their EID_{50} at 37°C, values are the means ± standard errors.

* Groups of mice were inoculated intranasally with 50 μl 10^6 EID_{50} of the indicated viruses. At 3 and 6 days post-inoculation, viral titers in lungs were determined by testing their EID_{50} at 37°C, values are the means ± standard errors.

* NO. of chickens or mice with detectable virus/total chickens or mice used.
| Vaccine groups | Challenging virus | Positive/total No. (HI antibody, log2) before challenge | Death rate | Shedding/trachea (log10EID50/ml ± SE) | Death rate | Shedding/cloacal (log10EID50/ml ± SE) | Death rate |
|----------------|------------------|------------------------------------------------------|------------|-----------------------------------|------------|-----------------------------------|------------|
| TS-C4/W1       | C4               | 0/6                                                  | ND (dead)  | ND (dead)                         | ND (dead)  | ND (dead)                         | ND (dead)  |
|                | C4               | 6/6                                                  | ND (dead)  | ND (dead)                         | ND (dead)  | ND (dead)                         | ND (dead)  |
| D6             | C4               | 5/6 (2.6)                                            | ND (dead)  | ND (dead)                         | ND (dead)  | ND (dead)                         | ND (dead)  |
| D6             | C4               | 0/6                                                  | ND (dead)  | ND (dead)                         | ND (dead)  | ND (dead)                         | ND (dead)  |
| C4/W1-PA(F35S) | C4               | 6/6                                                  | 0/6        | 0/6                               | 0/6        | 0/6                               | 0/6        |
| PBS            | C4               | 0/6                                                  | ND (dead)  | ND (dead)                         | ND (dead)  | ND (dead)                         | ND (dead)  |
days 3 and 6 p.i., three mice in each group were sacrificed, and lungs were removed and homogenized in 1 ml PBS containing penicillin and streptomycin. Viral titers were determined by EID$_{50}$ at 37°C. The results showed that viruses C4/W1-PA (F35S) and ts-C4/W1 grew up to lower titers than that of virus C4/W1 at 3 or 6 days p.i. (Table 1).

The PA subunit was reported to be critical in modulating ribonucleoprotein (RNP) activity under thermal stress (Kashiwagi et al., 2010) [18]. Effects of the ts mutation PA (F35S) on polymerase activity was analyzed at different temperatures (37°C and 41°C) using minigenome reconstitution assay as described previously (Sun et al., 2010) [19]. The RNP components of virus C4/W1 and C4/W1-PA (F35S) showed similar Luciferase activity at 37°C. However, at 41°C, the Luciferase activity of the RNP components of virus C4/W1 was 5.3-fold that of virus C4/W1-PA (F35S) (data not shown). The position 35 was near the endonuclease active site 41 of PA (Yuan et al., 2009) [20], whether the amino acid mutation PA (F35S) restricted the endonuclease activity of PA to some extent under thermal stress needed to be identified.

To determine the protective efficacy of the indicated vaccines in chickens, groups of twelve 3-week-old White Leghorn chickens were inoculated i.n. with 0.2 ml 10$^6$ EID$_{50}$ of the virus C4/W1-PA (F35S), ts-C4/W1 or 0.2 ml PBS. Three weeks post-vaccination, six chickens in each group were challenged with 100 50% chicken lethal dose (CLD$_{50}$) of either virus C4 (clade 9) or virus A/Duck/Hubei/hangmei01/2006 (H5N1) (D6) (clade 2.3.4) (Zou et al., 2009) [21], tracheal and cloacal swabs were collected at days 3 post-challenge (p.c.) for virus titration and chickens were observed for death and disease signs for two weeks. As shown in Table 2, virus C4/W1-PA (F35S) induced detectable HI antibody titers and can provide efficient protection against the same clade or cross-clade H5N1 HPAIV with undetectable viral titers from tracheal or cloacal swabs at 3 days p.c., while all the chickens received with virus ts-C4/W1 or PBS died.

Different sublineages of avian H9N2 influenza virus showed different pathogenicity to chickens or mice. Virus of A/Quail/Hong Kong/G1/97 sublineage with internal genes similar to the highly pathogenic Hong Kong/97 H5N1 influenza virus killed mice and spread to mouse brain, while virus of A/Duck/Hong Kong/Y280/97 H9N2 (Y280) sublineage were nonpathogenic to chickens or mice (Guo et al., 2000) [22]. Choosing a nonpathogenic H9N2 influenza virus as backbone might be safer and the stain W1 used in this study as avian backbone was the Y280-sublineage.

In light of rare LAIV used for poultry, we highlighted the potential of the new and simple ts mutation PA (F35S) in developing recombinant avian H5N1 LAIV with avian H9N2 influenza virus as backbone.

Competing interests
The authors declare that they have no competing interests.

Acknowledgement
We thank Dr. Richard Webby of St. Jude Children Research Hospital, Memphis, TN, USA for the pHW2000 plasmid, Dr. Hualan Chen of Harbin Veterinary Research Institute, China for pPoll-NP-Luc plasmid used in polymerase activity experiment and madam Liu Yanfei for critically reading of the manuscript. This work was supported by National Basic Research Program of China (program 973, grant 2011CB505004), the National Plan for Science and Technology Support (2010DAD04B03).

Authors’ contribution
WZ and JT performed the whole experiments. ZZ and HC analyzed the data. MJ designed the study and supervised the experiments. All authors read and approved the manuscript.

Received: 22 October 2011 Accepted: 23 May 2012 Published: 23 May 2012

References
1. Hwang SD, Kim HS, Cho SW, Seo SH: Single dose of oil-adjudanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus. Vaccine 2011, 29:2178–2186.
2. Watanabe T, Watanabe S, Kida H, Kawaoka Y: Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology 2002, 299:266–270.
3. Shinya K, Fujii Y, Ito H, Ito T, Kawaoka Y: Characterization of a neuraminidase-deficient influenza virus as a potential gene delivery vector and a live vaccine. J Virol 2004, 78:3083–3088.
4. Stech J, Gam H, Wegmann M, et al: A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 2005, 11:663–689.
5. Vincent AL, Ma W, Lager KM, Wagner R, Klenk HD: Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 2007, 25:7999–8009.
6. Ghendon YZ, Markushin SG, Akopova E, Koptiaeva IB, Nechaeva EA, Mazurkova LA, Radaeva IF, Kolokoltseva TD: Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine. Vaccine 2005, 23:4678–4684.
7. Lee JS, Kim HS, Seo SH: Genetic characterization and protective immunity of cold-adapted attenuated avian H9N2 influenza vaccine. Vaccine 2008, 26:6566–6576.
8. Lee KH, Seo SJ, Song JM, Lee OM, Kim HA, Seong BL: Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus. Vaccine 2006, 24:1966–1974.
9. Kiselova IV, Voeten JT, Teley LC, Larionova NV, van der Driessen Cruijnen SK, Basten SM, Heldens JG, van den Bosch HD, Rudenko LG: PB2 and PA genes control the expression of the temperature-sensitive phenotype of cold-adapted B/USSR/60/69 influenza master donor virus. J Gen Virol 2010, 91:951–967.
10. Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR, Subbarao K: Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003, 21:4430–4436.
11. Suguitan AL, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K: Live, attenuated influenza A HSN1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006, 3:e360.
12. Joseph T, McAuliffe J, Lu B, Vogel L, Swayne D, Jin H, Kemble G, Subbarao K: A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 2008, 387:133–132.
13. An WQ, Yang PH, Duan YQ, Luo DY, Tang C, Jia WH, Xing L, Shi XJ, Zhang YJ, Liu XF, Wang XL: Generation and characterization of a cold-adapted attenuated live H3N2 subtype influenza virus vaccine candidate. Chin Med J 2009, 122:2880–2885.
14. Song H, Nieto GR, Perez DR: A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J Virol 2007, 81:9238–9248.
15. Shi H, Liu XF, Zhang X, Chen S, Sun L, Lu J. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses. *Vaccine* 2007, 25:7379–7384.
16. Zhou H, Jin M, Chen H, Huag Q, Yu Z. Genome-sequence analysis of the pathogenic H5N1 avian influenza A virus isolated in China in 2004. *Virus Genes* 2006, 32:95–99.
17. Xu XJ, Xu GY, Zhou HB, Yu ZJ, Zhang AD, Song YJ, Jin ML, Chen HC. Evolutionary characterization of influenza virus A/duck/Hubei/W1/2004 (H9N2) isolated from central China. *Virus Genes* 2006, 32:79–83.
18. Kashiwagi T, Hara K, Nakazono Y, Hamada N, Watanabe H. Artificial hybrids of influenza A virus RNA polymerase reveal PA subunit modulates its thermal sensitivity. *PLoS One* 2010, 5:e15140.
19. Sun Y, Qin K, Wang J, Pu J, Tang Q, Hu Y, Bi Y, Zhao X, Yang H, Shu Y, Liu J. High genetic compatibility and increased pathogenicity of reassortants derived from avian H9N2 and pandemic H1N1/2009 influenza viruses. *Proc Natl Acad Sci USA* 2011, 108:4164–4169.
20. Yuan P, Bartlam M, Lou Z, Chen S, Zhou J, He X, Lv Z, Ge R, Li X, Tao D, Ervin F, Zhe R, Yingfang L. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. *Nature* 2009, 458:909–913.
21. Zou W, Yu Z, Zhou H, Tu J, Jin M. Genetic characterization of an H5N1 avian influenza virus with neurovirulence in ducks. *Virus Genes* 2009, 38(2):263–268.
22. Guo YJ, Krauss S, Senne DA, Mo JP, Lo KS, Xiong XP. Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. *Virology* 2000, 267:279–288.

doi:10.1186/1743-422X-9-97
Cite this article as: Zhang et al.: The new temperature-sensitive mutation PA-F35S for developing recombinant avian live attenuated H5N1 influenza vaccine. *Virology Journal* 2012 9:97.

Submit your next manuscript to *BioMed Central* and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit